Background. Rotavirus is recognized as a significant cause of pediatric gastroenteritis worldwide. Comprehensive data on the burden of rotavirus disease in Europe were lacking.
. Study-area populations and the number of hospitals, emergency departments, and primary care physicians participating in the study. Study been infected by 2-3 years of age [10, 11] , and many are infected more than once [12] . Five rotavirus serotypes (G1-G4 and G9) are responsible for ∼80% of RVGE cases worldwide [13, 14] , although the specific serotype that will be involved is unpredictable. Local intestinal immunity confers some protection against subsequent rotavirus infections [14] , with repeated infections becoming less severe or asymptomatic [11] . However, complete protection against the same or other rotavirus strains is not achieved [12] . Given the prevalence and consequences of RVGE, rotavirus is an obvious target for vaccination. An effective tetravalent vaccine introduced in 1998 was withdrawn after it was associated with a risk of intussusception [15] . Two new vaccines have recently been shown to provide high degrees of immunogenicity and protective efficacy: a naturally attenuated pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine containing G1-G4 and P [8] [16] and an attenuated G1P [8] monovalent human rotavirus vaccine [17] . The availability of these vaccines necessitates the development of an immunization strategy that takes account of the incidence of RVGE by age, causative serotypes, and total RVGE burden in Europe [18] . However, with rare exceptions [19] , only national studies have been reported, and their different methodologies make comparisons difficult.
Given this current lack of knowledge, we performed a prospective study of the epidemiologic profile of RVGE in 7 European countries. The primary objective of the Rotavirus Gastroenteritis Epidemiology and Viral Types in Europe Accounting for Losses in Public Health and Society (REVEAL) Study was to assess the annual incidence rates for AGE and RVGE in children !5 years of age seeking medical care in primary care, emergency department, and hospital settings in a specific study area in each country. The secondary objectives of the study, which are discussed elsewhere, were to describe the distribution of rotavirus serotypes associated with RVGE [20] , to describe the clinical impact of RVGE [21] , and to evaluate the economic and societal costs of RVGE [22] .
MATERIALS AND METHODS
Study design. The REVEAL Study was a prospective, multicenter, observational study of AGE in children !5 years of age in selected areas of 7 European countries: Belgium, France, Germany, Italy, Spain, Sweden, and the United Kingdom. Data were collected and analyzed for each country for a 12-month period (1 October 2004 -30 September 2005 .
The study was designed to determine the annual incidence rates for AGE and RVGE in children !5 years of age in primary care, emergency department, and hospital settings in a specific study area in each country, by use of the same protocol. The study was conducted in accordance with the 2004 amendment of the Declaration of Helsinki, the guidelines for Good Epidemiological Practice [23] , and local regulatory requirements. The protocol was approved by the local ethics committee in each study area.
Sample size calculations. Although the study was descriptive and no hypotheses were tested, we estimated the number of children to be included (by use of Epi-Info software [version Figure 1 . Summary of eligibility assessment and inclusion in the study. Across all study-entry points, 8301 children with acute gastroenteritis (AGE) were assessed for eligibility. However, in the figure, 8903 children are shown as having been assessed for eligibility, comprising 1212 children assessed in hospitals, 3377 children assessed in emergency departments, and 4314 children assessed in the sample of primary care practices. This is because the children who were referred from their study-entry setting to another setting are shown as being assessed in both the study-entry setting and the setting to which they were referred. Thus, the 8903 children comprise 8301 unique patients with AGE plus 75 children referred from emergency departments plus 527 children referred from primary care practices. Reasons for noneligibility and for noninclusion of eligible children, as well as data for nonincluded eligible children that were recorded on a screening list, are detailed in the "Inclusion and exclusion criteria" subsection of Materials and Methods.
a Although patients referred on from the study-entry setting are shown in the entry-setting path, detailed data for the AGE episode were collected and were included only at the highest referral level.
6; Centers for Disease Control and Prevention]), to ensure that the sample size was sufficiently large to provide precise estimated data. We calculated that, for an expected RVGE-associated hospitalization rate of 0.4% among children !5 years of age in France [24] , with a precision of 0.01 and 95% confidence intervals, a sample of 15,304 children !5 years of age was required per study area. Taking into account that children !5 years of age represent 5.4% of the French population, the size (N) of the population in each area was computed using the following equation:
. It was assumed that this N p 15,304/0.06 calculation would be similar for all study areas, and, consequently, because , a study area with 15,304/0.06 p 255,066 ∼255,000 inhabitants was required in each country. In Germany and Italy, the percentages of children !5 years of age were lower (∼3.7% and ∼4.1% of the population, respectively), and, therefore, larger areas were selected (table 1).
Using published annual incidence data for AGE and the proportion of RVGE in European countries [31] [32] [33] [34] [35] [36] [37] [38] and of visits to a general practitioner for RVGE [19, [39] [40] [41] , we estimated that ∼534 stool specimens would be collected from children with AGE in each study region. It was predicted that ∼150 of these specimens would be found to be rotavirus positive.
Selection of study areas. Within each country, a study area was selected to comprise a middle-sized city or town of 100,000-250,000 inhabitants and a surrounding rural population of ∼100,000. The study areas selected were as follows: Figure 2 . Estimations for the eligible children not included in the study and the no. of children with acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE). The example uses data for children in primary care settings in Italy. For the example, calculations were as follows: the no. of eligible children seen in primary care settings was 568, of whom 408 (71.8%) were enrolled in the primary care setting; the other children were referred to a higher level of care. This percentage (71.8%) was used to estimate that, of the 43 eligible children who were not included in the study, 31 would have been included in the primary care setting. The estimated no. of children with AGE is , where 6338 [(408 + 31)/6338] ϫ 16,000 p 1108 is the no. of children who consulted primary care physicians participating in this study area and 16,000 is the total no. of children For each of the selected study areas, all hospitals and emergency departments that might see children with AGE were included in the study, along with a convenience sample of primary care physicians (general practitioners and/or pediatricians) within the catchment area. The number of primary care physicians needed was calculated to ensure coverage of a population of ∼5000 children !5 years of age, allowing for the collection of ∼50-60 rotavirus-positive specimens in this setting. Details regarding the populations and participating settings are summarized in table 1.
Inclusion and exclusion criteria. All children !5 years of age who were living within a defined study area during the study period and seeking medical intervention for AGE were eligible for inclusion in the study. AGE was defined as an episode of at least 3 loose stools, at least 3 watery stools, or forceful vomiting associated with gastroenteritis occurring during a 24-h period in the 7 days before the medical visit; the episode must have been preceded by a symptom-free period of 14 days. Children were not eligible for inclusion if they had a previously diagnosed chronic disease of the gastrointestinal tract for which symptoms were compatible with the definition of AGE (e.g., celiac disease or Hirschsprung disease), if they had participated in a rotavirus vaccine trial, or if they had nosocomial AGE. Eligible children whose parents did not provide written, informed consent and whose parents had no access to a telephone were classified as "not included eligible children." Also, children whose parents did not speak the native language of the country were classified as "not included eligible children," because they could have had difficulties completing the study forms. Data on these children were recorded on a "screening list," which contained details about their age group (!3 months, 3-5 months, 6-11 months, 12-23 months, 24-35 months, 36-47 months, or 48-59 months of age) and consultation date. The screening list of not included eligible children was used in the In the German study area, all eligible children who presented to the emergency department with acute gastroenteritis during the study were referred to the hospital, so there were no inclusions for the emergency department setting. c In the primary care setting in the Swedish study area, parents generally called a nurse advice service located in the same medical center as the primary care physicians. Therefore, on the basis of the nurses' advice, most children with acute gastroenteritis were referred to higher care or treated at home.
calculations of estimates (see below). Primary care physicians also provided data on the number of children !5 years of age who had consulted with the physicians for any reason during the study period. If a child visited 11 health care facility during the AGE episode, the data relating to the highest level of care were included in the study. The level of care increased in the following order: primary care, emergency department care, and hospital care.
Thus, a child who consulted a primary care physician and also required hospitalization was considered to be entering the study in the hospital setting. Children presenting more than once during the study period were considered to be separate cases. In the German study area, there were no inclusions for the emergency department setting, because all eligible children consulting at emergency departments were referred to the hospital, and they were therefore included in the hospital setting. Figure Figure 3 . Observed percentage (and 95% confidence interval) of cases of acute gastroenteritis (AGE) due to rotavirus, by study area and setting. In the German study area, all eligible children who presented to the emergency department with AGE during the study were referred to the hospital, so there were no inclusions for the emergency department setting.
1 provides a summary of how children were included in the study.
Data collection. Data for each child were collected via a series of questionnaires. At baseline, the investigator completed a questionnaire gathering details about inclusion criteria, environmental factors (e.g., breast-feeding), health care utilization related to the AGE episode before the inclusion visit, medication prescribed, and laboratory tests performed during the inclusion visit. The parents also completed a baseline questionnaire that provided data on sociodemographic and environmental factors (e.g., the education and employment status of the parents, the number of children and adults in the household, and daytime child care).
For hospitalized children, a follow-up questionnaire was completed by the treating nurse and/or the parents, to provide information on the nature and duration of symptoms of AGE, laboratory tests performed, and rehydration therapy (intravenous fluids or oral rehydration solutions) administered. For all children, the parents completed a follow-up questionnaire at the end of the episode, to provide information on the nature and duration of symptoms, additional health care utilization resulting from AGE since the time of the study inclusion visit, and other parameters associated with the costs of RVGE (e.g., medication received at home, the number of workdays lost by the parents, the number of days of exclusion from child care settings, alternative arrangements for child care that were made, transportation, and use of extra diapers).
One stool sample from each child was obtained for rotavirus testing within 14 days of the onset of symptoms (ideally, within the first 3 days of the onset of symptoms). An ELISA was used to identify rotavirus as the etiological agent [42] . Full details of the sample collection procedures and analytical methods used are provided elsewhere [20] . Children with a positive ELISA result were classified as having RVGE. Samples found to be rotavirus positive by ELISA underwent reverse-transcription polymerase chain reaction, followed by sequencing for identification of G serotypes [43] . The results of these analyses are presented elsewhere [20] .
Calculation of estimated numbers of children and incidence rates. To estimate the overall data for each study area by extrapolating data from children included in the study, the number of children who could have been recruited through hospital, emergency department, and primary care settings was estimated for each area, taking into account response rates and, for the primary care setting, the sampling fraction (the number of children seen by primary care physicians participating in the study divided by the total number of children living in the study area) (table 1). These estimates were then used as the numerators in the calculation of the estimated incidence rates for AGE and RVGE in each study area.
For the hospital and emergency department settings, the denominator used in the calculation of the annual incidence rates for AGE and rotavirus-positive infections in children !5 years of age was the number of children in the catchment area. The numerators were the numbers of children included in the study, taking into account both the number of eligible nonincluded children in the area and the response rates in each setting (figure 2). It was assumed that (1) the incidence and characteristics of AGE and rotavirus-positive infection, as well as the outcomes among children not included in the study, were similar to those of children included in the study; and (2) all eligible children with AGE in the study area would have consulted the hospitals or emergency departments participating in the study.
The numerators used in the calculation of the incidence rates in the primary care setting were derived from the number of children included in the study at the primary care level, taking into account the response rate, and were divided by the total number of children living in the study area, under the assumption that the characteristics of and outcomes for eligible children not included in the study were similar to those noted NOTE. NA, not applicable; NC, not calculated a 95% confidence intervals were not estimated because only 5 and 14 children, respectively, were included in these settings b In the German study area, all eligible children who presented to the emergency department with AGE during the study were referred to hospital, so there were no inclusions for the emergency department setting. c In the primary care setting in the Swedish study area, parents generally called a nurse advice service located in the same medical center as the primary care physicians. Therefore, on the basis of the nurses' advice, most children with AGE were referred to higher care or treated at home. for children included in the study. The denominator was the total number of children !5 years of age who were seen by a primary care physician during the 12-month study (figure 2). Area-specific population data were used in the age-specific distribution calculations, except in Spain, Italy, and Germany, where only the national age distributions were available. We computed 95% confidence intervals around the observed proportions of RV-positive children among children with AGE. The corresponding numbers of RV-positive children (upper and lower limits) were extrapolated using sampling fractions and participation rates.
Statistical analyses. Statistical analyses were performed using SAS software (version 8.2; SAS Institute). Qualitative data (e.g., sex and health care utilization) were summarized in frequency tables, and quantitative data (e.g., age and duration of symptoms) were summarized with quantitative descriptive statistics (e.g., frequency, mean, SD, median, and range values).
RESULTS

Study populations.
Across the 7 study areas, 12 hospitals, 18 emergency departments, and 139 primary care practices participated in the study. Overall, 8301 children were assessed for eligibility. Of these children, 7082 (85.3%) were eligible for inclusion in the study and 2846 (40.2%) of the 7082 children were included. The most common reasons for noninclusion of the remaining 4236 children were lack of parental consent (58%-97% of children) and an inability to speak the native language (3%-42% of children).
The number of children included in each study region varied from 127 children in Belgium to 801 children in Spain (table  2) . ELISA results were available for 2712 children, and, of these children, 1102 (40.6%) were found to be rotavirus positive. ELISA results were not available for 134 children either because the sample was insufficient or because the test result was not interpretable.
Percentage of AGE cases due to rotavirus, by study area and setting. The overall estimated percentages of AGE cases due to rotavirus were 44.7% in Belgium, 33.5% in France, 27.8% in Germany, 43.6% in Italy, 31.2% in Spain, 52.0% in Sweden, and 35.9% in the United Kingdom. Although the percentage varied between study areas, up to 68.8%, 63.5%, and 41.0% of AGE cases were observed to result from rotavirus in the hospital, emergency department, and primary care settings, respectively (figure 3). If we consider that children with severe AGE would be more likely to seek medical care in either a hospital or emergency department setting, it is interesting to note that, among children seeking medical care for AGE at either hospitals or emergency departments, the proportions of children with RVGE were 49% in Belgium, 44% in France, 62% in Germany, 58% in Italy, 38% in Spain, 59% in Sweden, and 58% in the United Kingdom. Although the percentages varied between study areas, among the children seeking medical care in either a hospital or an emergency department setting, ∼50% overall had AGE due to rotavirus, compared with ∼27% of those seeking medical care in a primary care setting.
Estimated annual incidence rates for AGE and RVGE. The estimated overall cumulative annual incidence rates for AGE ranged from 4.22 cases/100 children in Sweden to 16.82 cases/ 100 children in Germany (table 3) . The range of annual incidence rates for RVGE was narrower, from 2.07 cases/100 children in the United Kingdom to 4.96 cases/100 children in France. Incidence rates for both AGE and RVGE appeared to be lower in Sweden and the United Kingdom than in the other countries.
RVGE accounted for 18.1%-31.9% of AGE episodes in children !6 months of age in France, Germany, Italy, Spain, and the United Kingdom; in Sweden and Belgium, there were only 1 and 9 children with RVGE, respectively; therefore, the estimated incidence rates should be interpreted with caution (table  4) . The estimated age-specific annual incidence rates for RVGE were consistently higher in the groups of children who were 6-11 months and 12-23 months of age than in the other age groups, in all study areas (table 4), with 56.7%-74.2% of all RVGE cases occurring in the 6-23-month age group (figure 4). The age-specific annual incidence rates for RVGE ranged from 1.05 to 5.44 cases/100 children in the 1-5-month age group (excluding Sweden and Belgium [see above]), from 1.50 to 3.96 cases/100 children in the 24-35-month age group, and from 0.31 to 2.10 cases/100 children in the 36-59-month age group (table 4) .
Estimated seasonal distribution of AGE and RVGE. AGE occurred most frequently between October and May, with a peak incidence occurring between January and March. The season for RVGE was shorter, extending from December to April, but the peak incidence of RVGE was also between January and March. The peak incidences of AGE and RVGE occurred slightly later (in April) in Sweden than in the other countries. Data on the seasonal distribution of specific serotypes are reported elsewhere [20] .
DISCUSSION
The REVEAL Study is, to our knowledge, the first study to investigate systematically RVGE requiring medical care across Europe, by use of a common protocol in 3 settings (primary care, emergency department, and hospital settings). The results suggest that RVGE accounts for a substantial proportion of the disease burden associated with AGE in children !5 years of age across all 7 study areas. The estimated annual incidence rates for AGE ranged from 4.22 to 16.82 cases/100 children, whereas those for RVGE ranged from 2.07 to 4.96 cases/100 children. Incidence rates for RVGE were highest for children aged 6-23 months, with 56.7%-74.2% of all RVGE cases occurring in children in this age group. Overall, RVGE was estimated to account for 27.8%-52.0% of AGE cases. RVGE was responsible for up to two-thirds of hospitalizations and emergency department consultations, as well as one-third of primary care consultations for AGE during the study period.
The REVEAL Study has a number of major strengths, compared with previous studies conducted on this topic. It prospectively included a large number of children (12800) who entered the study during an entire season in 7 different European areas where the same protocol was used. Each study area had comparable population profiles and sizes, and each included both urban and rural communities. In contrast with previous studies that have generally focused only on single health care settings, data were collected from children seen in 3 health care settings-hospital, emergency department, and primary care settings. Moreover, a central laboratory was used to perform rotavirus ELISA.
Some potential limitations of this investigation should be mentioned. Calculations of incidence rates relied on extrapolation of observed data to the whole population of each study area, on the basis of the assumption that nonincluded children with AGE or RVGE would have similar characteristics. We cannot exclude the possibility that nonparticipation or noninclusion may be strong confounding factors, with younger age being a likely reason for noninclusion. It is also important to remember that rotavirus-negative AGE can be caused by a variety of pathogens, which we did not look for in this study, because we aimed to evaluate the burden of rotavirus disease. The population of children with rotavirus-negative AGE, therefore, would likely be more heterogeneous than the population with RVGE, as defined by our inclusion criteria. Other potential biases include the selection of study areas on the basis of physicians' willingness to participate, the fact that only children seeking health care were identified, and the socioeconomic status of the parents and the severity of their child's disease (both of which may have influenced the willingness to participate).
Some factors may have led to underestimation of the RVGE incidence rates. Patterns of referral from lower to higher levels of care probably differ among the study regions, leading to an underestimation of the disease burden in some settings. In addition, the actual number of RVGE episodes may have been higher, because only samples for which ELISA results were positive were considered to be rotavirus positive, whereas it has been reported that samples for which ELISA results were negative have been found to be rotavirus positive by means of polymerase chain reaction [44, 45] . Furthermore, we specifically excluded children with nosocomial RVGE.
In contrast, one particular factor may have led to overestimation of the incidence rates for AGE and RVGE in the primary care setting. The denominators for the primary care settings were based on the number of children !5 years of age seen by participating primary care physicians during the study period. It is possible, however, that not all children !5 years of age were included by those physicians who did not use computerized records but, instead, counted by hand the data from patient lists.
Although some caution might be required in the interpretation and extrapolation of our findings, our estimates of the annual incidence rates of RVGE show that rotavirus is a major cause of AGE in all countries. Several previous studies have reported the incidence and hospitalization rates for RVGE, but direct comparisons are either limited or not possible because of differences in the definitions of disease, selected study populations, and other methods used by different studies. Studies in the primary care setting have reported annual RVGE incidence rates (per 100 children) of 1.4 cases in Austria [19] , 6.6 and 4.0 cases in Germany [19, 41] , 1.5 cases in Spain [46] , and 2.9 cases in Switzerland [19] . Annual rates of hospitalization due to RVGE (per 100 children) have previously been reported to be 0.5 case in the United Kingdom [36] , 0.8 case in Germany [35] , and 0.1 case in Spain [47] , which are similar to the rates reported in the present study.
For children seen in primary care settings in the United Kingdom and Austria, it has been reported that 29% and 34%, respectively, of AGE cases are due to rotavirus [48, 49] . In Italy and Spain, 27% [50] and 31% [51] , respectively, of children who were hospitalized for AGE were found to have rotavirus infections. The percentages of children hospitalized were reported to be 41% in Germany [35] , 43% in England and Wales [36] , and 31%-51% in France [52, 53] . These percentages clearly are lower than the estimated percentages in the current study; however, it is possible that our results might simply reflect the epidemiologic profile of rotavirus for this particular study period. The differences in the incidence in the different study areas and settings could be explained by differences in the health care referral systems throughout Europe. In some areas, for example, children may have been more likely to be managed at home, and, therefore, these children would not be included in our incidence calculations.
Our finding that the majority of cases of RVGE occurred in children 6-23 months of age is consistent with previous observations of the epidemiologic profile of rotavirus infection [2, 5, 9, 54] . This finding can be explained by the protective effect of maternal antibodies in infants !6 months of age and, also, by the development of natural immunity after successive infections in children 12 years of age [55, 56] .
Our results show that the greatest burden of AGE occurred between October and May in all countries and peaked between January and March, whereas, for RVGE, the period of greatest burden was shorter (December to April), although the peak also occurred between January and March. These observations are consistent with previous reports of rotavirus infections in Europe [9, 51, 57] . The high rate of hospitalization due to RVGE over a short period has an important influence on health care services, because this coincides with the peak incidences of other diseases occurring in winter (e.g., respiratory tract infections caused by respiratory syncytial virus or influenza virus), thus placing a considerable burden on hospital services [58] .
Rotavirus infections account for a significant proportion of AGE cases in infants and young children in Europe. Although the results from the REVEAL Study might have underestimated the true total burden of RVGE, they do show that RVGE was responsible, in some areas, for up to two-thirds of all hospitalizations and emergency department visits associated with AGE in children !5 years of age. The burden of this frequent, potentially serious childhood disease in Europe could be reduced by routine rotavirus vaccination of infants. Because RVGE appears to occur more frequently from 6 to 24 months of age, vaccination before 6 months of age should be recommended. The REVEAL Study has provided essential data and knowledge for assessing the influence of introducing rotavirus vaccination on public health. 
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